Surface Oncology has entered a collaboration with Merck to investigate a combination of SRF617 and Keytruda (pembrolizumab) in patients with solid tumors, with a particular focus on individuals with gastric cancer and those who failed to respond to immune checkpoint inhibitors. This combination will be investigated as part of the first-in-human Phase 1/1b clinical trial of SRF617, Surface’s investigational anti-CD39 antibody. The trial is assessing the safety and efficacy of SRF617, alone and in combination…
You must be logged in to read/download the full post.
The post Surface, Merck Partner on SRF617-Keytruda Combo Targeting Solid Tumors appeared first on BioNewsFeeds.